STOCKS | Eli Lilly's Retatrutide Meets Primary Endpoints in Phase III Trial
2026-07-23 10:49:26
According to Jin10, Eli Lilly (LLY.N) said Retatrutide achieved significant weight-loss results and met the primary endpoints in Phase III trials.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Mobileye Founder Amnon Shashua to Step Down as CEONext article：
Eli Lilly Weight-Loss Shot Clears Heart-Risk Study
